What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Ezra E.W. Cohen mostly deals with Internal medicine, Oncology, Cancer, Surgery and Head and neck cancer.
His Internal medicine and Phases of clinical research, Carcinoma, Epidermal growth factor receptor, Clinical endpoint and Hazard ratio investigations all form part of his Internal medicine research activities.
Ezra E.W. Cohen has researched Oncology in several fields, including Thyroid cancer, Cetuximab and Chemotherapy, Docetaxel.
His Cancer research focuses on Pathology and how it connects with Metastasis, Cyclin D1 and Adenoviridae.
His Surgery research integrates issues from Gastroenterology, Clinical trial and Intensive care medicine.
His Head and neck cancer research includes themes of Regimen, Chemoradiotherapy, Fluorouracil and Quality of life.
His most cited work include:
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (4170 citations)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (1933 citations)
- Cabozantinib in Progressive Medullary Thyroid Cancer (644 citations)
What are the main themes of his work throughout his whole career to date?
Ezra E.W. Cohen mainly investigates Internal medicine, Oncology, Head and neck cancer, Cancer and Head and neck squamous-cell carcinoma.
Ezra E.W. Cohen interconnects Surgery and Head and neck in the investigation of issues within Internal medicine.
His Oncology study deals with Radiation therapy intersecting with Concomitant.
His studies deal with areas such as Locally advanced, Chemoradiotherapy, Targeted therapy and Fluorouracil as well as Head and neck cancer.
His Head and neck squamous-cell carcinoma study combines topics from a wide range of disciplines, such as Cancer research, Methotrexate, Afatinib, Clinical endpoint and Immunotherapy.
The Cancer research study combines topics in areas such as PI3K/AKT/mTOR pathway, Epidermal growth factor receptor and Pathology.
He most often published in these fields:
- Internal medicine (60.17%)
- Oncology (50.54%)
- Head and neck cancer (26.55%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (60.17%)
- Oncology (50.54%)
- Head and neck squamous-cell carcinoma (18.84%)
In recent papers he was focusing on the following fields of study:
Ezra E.W. Cohen spends much of his time researching Internal medicine, Oncology, Head and neck squamous-cell carcinoma, Pembrolizumab and Cancer research.
His work on Chemotherapy, Head and neck cancer and Cancer as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines.
His Head and neck cancer study integrates concerns from other disciplines, such as Clinical trial and Intensive care medicine.
His Oncology research is multidisciplinary, incorporating elements of Cetuximab, Regimen, Docetaxel, Nivolumab and Cohort.
His Head and neck squamous-cell carcinoma research incorporates elements of Programmed death, Methotrexate, Open label, Afatinib and Clinical endpoint.
His research integrates issues of Agonist, Cell, T-cell receptor and Immunotherapy in his study of Cancer research.
Between 2017 and 2021, his most popular works were:
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (409 citations)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (115 citations)
- Positive Surgical Margins in the 10 Most Common Solid Cancers (58 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Ezra E.W. Cohen mainly focuses on Head and neck squamous-cell carcinoma, Internal medicine, Oncology, Pembrolizumab and Cancer research.
His Head and neck squamous-cell carcinoma study is focused on Cancer in general.
Hazard ratio, Regimen, Clinical endpoint, Radiation therapy and Methotrexate are subfields of Internal medicine in which his conducts study.
His Oncology study integrates concerns from other disciplines, such as Cetuximab, Pharmacokinetics and Docetaxel, Chemotherapy, Adjuvant therapy.
Ezra E.W. Cohen works mostly in the field of Cetuximab, limiting it down to topics relating to Epidermal growth factor receptor and, in certain cases, Biomarker.
In his research, Head and neck cancer, Receptor, Antigen and CD8 is intimately related to Immunotherapy, which falls under the overarching field of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
